Full-Time

Automation Engineer 2

Support Applications Engineering

Ginkgo Bioworks

Ginkgo Bioworks

501-1,000 employees

Platform for cell programming and engineering

Compensation Overview

$85.6k - $120.2k/yr

+ Stock awards

Boston, MA, USA

In Person

On-site five days per week in Boston; overnight graveyard shift from 10 PM to 6 AM.

Bachelor's

Category
Solution Engineering (1)

Get referred to Ginkgo Bioworks

See people who can refer or advise you

Requirements
  • A bachelor's degree in Engineering, Life Sciences, or a related technical field, and 4–7 years of relevant experience in laboratory automation, systems integration, or related technical work; alternatively, an equivalent combination of education and progressively responsible hands-on experience, typically 6+ years total, demonstrating the same level of knowledge and ability.
  • The ability to adapt in fast-paced environments and solve problems proactively.
  • A customer-focused approach that balances customer needs with technical feasibility.
  • Strong interpersonal and teamwork skills, including the ability to convey concepts and priorities and solicit or accept feedback.
  • The ability to manage time and tasks with minimal supervision.
  • The ability to travel occasionally to customer sites for 1–2 weeks to conduct site acceptance testing, comprising less than 10% of total time.
  • The ability to bend, reach, lift, push, or pull up to 25 pounds, stand or walk for long periods, and perform repetitive actions when required.
  • Strong communication skills and the ability to clearly explain technical concepts to technical and non-technical audiences.
  • The ability to work on-site five days per week in Boston on a graveyard shift from 10 PM to 6 AM.
Responsibilities
  • Own Ginkgo’s Autonomous Lab during overnight hours by recovering from errors, performing instrument maintenance, and addressing user tickets.
  • Execute or guide remote recovery efforts with customers by diagnosing root causes and executing corrective actions for instrument- or integration-level failures.
  • Lead root-cause investigations for complex software-hardware integration failures, synthesize findings, and choose corrective actions that improve time between failures and overall reliability.
  • Develop and validate automation scripts and configuration templates that standardize installations and reduce manual effort across the Deployment team.
  • Create and continuously refine end-to-end deployment playbooks covering initial setup and configuration of automation products, factory acceptance testing, and site acceptance testing.
  • Author and own standard operating procedures, troubleshooting guides, and training materials to keep documentation compliant, accessible, and maintained as a single source of truth.
  • Perform and periodically audit the recurring preventive-maintenance program, ensuring tasks, frequencies, and parts lists meet reliability goals.
  • Train and certify customer operators and technicians on preventive-maintenance execution.
Desired Qualifications
  • Experience in a customer-facing role involving an explicit Service Level Agreement.
  • Experience operating, troubleshooting, or maintaining laboratory automation equipment or other complex automated machinery.
  • Experience in the Life Science industry, ideally in a laboratory or research setting.
  • A proven track record of working in high-stakes environments and contributing to scientific advancements and operational improvements.
  • Experience with workflow or process scheduling software or multi-device systems.
  • Expertise managing complex workflows and integrating multiple devices to optimize laboratory processes and productivity.

Ginkgo Bioworks offers a platform-based approach to cell programming for diverse industries such as food, agriculture, pharma, and chemicals. Its Foundry is an automated lab system that designs, builds, and tests engineered organisms, while the Codebase is a growing library of genetic parts and experimental data that informs new projects, all tied together by a Design-Build-Test-Learn loop for fast prototyping. The company earns revenue from Foundry-based R&D services and from Downstream Value, which can include royalties, milestone payments, or equity in partner companies. Its goal is to make biology easier to engineer and speed up the development of biological products through end-to-end tooling and data-driven workflows.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2009

Get referred to Ginkgo Bioworks

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue of $20 million beat expectations and showed tighter cost control.
  • Ginkgo held $373 million cash at March 31, 2026, with no bank debt.
  • Invaio collaboration on February 18, 2026 expands crop-protection applications beyond pharmaceuticals.

What critics are saying

  • Revenue fell 49% year over year to $19 million in Q1 2026.
  • Management guided 2026 cash burn of $125 million to $150 million, despite cuts.
  • If cloud lab adoption stalls, Ginkgo's shrinking revenue cannot fund Nebula before 2028.

What makes Ginkgo Bioworks unique

  • Ginkgo Cloud Lab launched March 2, 2026, offering 70-plus instruments through browser access.
  • OpenAI's GPT-5 collaboration validated 36,000 experiments and cut protein costs 40%.
  • PNNL chose Ginkgo in January 2026 for one of DOE's largest autonomous labs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited paid time off

Comprehensive health and parental leave benefits

Flexible work options

Commuter benefits

State-of-the-art labs, work spaces, and conference rooms

Competitive 401K contribution

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

-3%
Yahoo Finance
May 10th, 2026
Ginkgo Bioworks pivots to autonomous labs as Q1 revenue falls 49% to $19M

Ginkgo Bioworks is refocusing on autonomous laboratories following the divestiture of its biosecurity business, which closed on 3 April. The biosecurity spin-off created a new company called Perimeter and brought in $60 million, with Ginkgo retaining a shareholding. CEO Jason Kelly said the company's 2026 investment priorities centre on winning the autonomous lab category through running services on its Boston-based Nebula system and selling autonomous lab systems to early adopters like Pacific Northwest National Laboratory. First-quarter revenue from continuing operations fell 49% year-over-year to $19 million, though excluding a $7.5 million non-cash item from 2025, the decline was 37%. Operating expenses dropped significantly, with research and development costs down 38% to $30 million and general and administrative expenses falling 35% to $13 million.

Yahoo Finance
Mar 15th, 2026
Ginkgo Bioworks price targets cut as analysts split on automation lab rollout and cash burn

Analysts have trimmed price targets on Ginkgo Bioworks, with bullish views dropping to $12 from $14 and bearish targets falling to $5 from $9. The revisions reflect mixed sentiment around execution risk and recent business changes. TD Cowen maintained a Buy rating at $12, citing multi-year growth frameworks and improving investor sentiment ahead of 2026 guidance updates. BTIG kept its Sell rating at $5, noting it wants better visibility into how Ginkgo will monetise autonomous labs following the biosecurity business divestiture. Ginkgo recently launched Ginkgo Cloud Lab, a browser-based platform for running benchwork on autonomous lab infrastructure. The company announced collaborations with OpenAI on GPT-5-based biological experiments and with Invaio Sciences on microbial strains for crop protection.

PR Newswire
Mar 2nd, 2026
Ginkgo Bioworks launches cloud lab with AI-powered autonomous infrastructure

Ginkgo Bioworks has launched Ginkgo Cloud Lab, a web-based interface allowing researchers to access the company's autonomous laboratory infrastructure remotely. The platform runs on proprietary Reconfigurable Automation Carts, which combine robotic arms, maglev sample transport and industrial software. The Cloud Lab provides access to over 70 instruments covering biological operations including sample preparation, liquid handling and analytical readouts. Its AI-driven agent, EstiMate, enables scientists to submit protocols in natural language and receive immediate compatibility assessments and pricing. The launch supports Ginkgo's 2026 strategy to transition all R&D services to Nebula, its autonomous lab in Boston, and phase out traditional laboratory benches. The company is inviting researchers from academia and biopharmaceutical firms to test the platform at cloud.ginkgo.bio.

Yahoo Finance
Mar 1st, 2026
Ginkgo Bioworks falls 30% despite Invaio peptide crop protection collaboration and $250M cost savings

Ginkgo Bioworks has reported full-year 2025 results showing lower revenue at $170.16 million and a reduced net loss of $312.76 million, alongside announcing a collaboration with Invaio Sciences on peptide-based crop protection. Despite this, shares declined 30.48% in one day to $6.75. The biotech company has achieved $250 million in annual cost savings and maintains a strong balance sheet with $474 million in cash and no bank debt. Analyst estimates suggest the stock is 32.5% undervalued, with a fair value of $10 per share. However, the company faces significant headwinds, with shares down 22.41% year-to-date and 87.86% over three years. Key risks include slower adoption of its AI and automation platform and margin pressure from underutilised laboratory capacity.

Yahoo Finance
Feb 28th, 2026
Ginkgo Bioworks pivots to autonomous labs, plans biosecurity spin-off amid revenue decline

Ginkgo Bioworks has outlined a 2026 strategy centred on autonomous labs, whilst reporting declining cell engineering revenue and improved cash burn. The company will concentrate capital on its Nebula system in Boston, expand capacity towards 100 racks, and commercialise offerings including Solutions, Datapoints and cloud lab services integrated with AI. Cell engineering revenue fell 26% year-on-year in Q4, with full-year revenue of $133 million versus $174 million in 2024. However, R&D and G&A cuts improved losses, reducing cash burn to $171 million for 2025. Management is guiding cash burn of $125–$150 million for 2026. The company plans to spin off its biosecurity business to outside investors whilst retaining a minority stake, freeing capital for autonomous lab investments.